Cell-derived membrane biomimetic nanocarriers for targeted therapy of pulmonary disease

Xixi Zheng; Tianyuan Zhang; Ting Huang; Yanjun Zhou; Jianqing Gao

doi:10.1016/j.ijpharm.2022.121757

Cell-derived membrane biomimetic nanocarriers for targeted therapy of pulmonary disease

Int J Pharm. 2022 May 25:620:121757. doi: 10.1016/j.ijpharm.2022.121757. Epub 2022 Apr 18.

Authors

Xixi Zheng¹, Tianyuan Zhang², Ting Huang², Yanjun Zhou³, Jianqing Gao⁴

Affiliations

¹ Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
² Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
³ Zhejiang Huanling Pharmaceutical Technology Company, Jinhua 321000, China.
⁴ Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Jinhua Institute of Zhejiang University, Jinhua 321002, China; Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China. Electronic address: gaojianqing@zju.edu.cn.

Abstract

Pulmonary diseases are currently one of the major threats of human health, especially considering the recent COVID-19 pandemic. However, the current treatments are facing the challenges like insufficient local drug concentrations, the fast lung clearance and risks to induce unexpected inflammation. Cell-derived membrane biomimetic nanocarriers are recently emerged delivery strategy, showing advantages of long circulation time, excellent biocompatibility and immune escape ability. In this review, applications of using cell-derived membrane biomimetic nanocarriers from diverse cell sources for the targeted therapy of pulmonary disease were summarized. In addition, improvements of the cell-derived membrane biomimetic nanocarriers for augmented therapeutic ability against different kinds of pulmonary diseases were introduced. This review is expected to provide a general guideline for the potential applications of cell-derived membrane biomimetic nanocarriers to treat pulmonary diseases.

Keywords: Biomimetic; Cell membrane; Lung targeting; Nanoparticles; Pulmonary disease.

Publication types

Review

MeSH terms

Biomimetic Materials*
Biomimetics
COVID-19 Drug Treatment*
Cell Membrane / metabolism
Drug Carriers / metabolism
Drug Delivery Systems
Humans
Nanoparticles*
Pandemics

Substances

Drug Carriers